Loading...
Loading...
Browse all stories on DeepNewz
VisitWill there be a reported increase in black market tobacco activity by end of 2025?
Yes • 50%
No • 50%
Reports from law enforcement and regulatory agencies
Biden's 11th Hour Proposal to Lower Nicotine in Cigarettes Clears FDA Review, Raises Organized Crime Concerns
Jan 7, 2025, 08:15 PM
The Biden administration is advancing a proposal to lower nicotine levels in cigarettes, a move that has cleared a regulatory review by the Food and Drug Administration (FDA). This proposal, which aims to reduce the addictiveness of cigarettes and certain other combusted tobacco products, could effectively ban cigarettes currently on the market in favor of products with lower nicotine levels. Critics, including Rich Marianos, a former assistant director of the U.S. Bureau of Alcohol, Tobacco, Firearms and Explosives, argue that the change could inadvertently benefit organized crime cartels by boosting the black market for tobacco products. The FDA, led by Commissioner Robert Califf, has stated that the proposed rule, titled 'Tobacco Product Standard for Nicotine Level of Certain Tobacco Products,' completed its regulatory review on January 3, but has not yet been finalized. This 11th hour proposal is seen as a significant step in U.S. tobacco product regulation, aiming to help both current smokers quit and prevent future generations from becoming addicted.
View original story
No • 50%
Yes • 50%
Decreased support • 25%
Increased support • 25%
No significant change • 25%
Mixed opinions • 25%
No significant change • 25%
Decrease by 1-5% • 25%
Decrease by more than 5% • 25%
Increase • 25%
Significant decline (more than 10%) • 25%
Moderate decline (5-10%) • 25%
Little to no change • 25%
Increase • 25%
No change • 25%
Significant decrease • 25%
Minor decrease • 25%
Increase • 25%
Increase by more than 5% • 25%
Data not available • 25%
No significant change (±5%) • 25%
Decrease by more than 5% • 25%
Implemented without changes • 25%
Implemented with modifications • 25%
Blocked by legal challenges • 25%
Withdrawn by FDA • 25%
Product reformulation • 25%
Other • 25%
Legal challenge • 25%
Compliance • 25%
Decrease by over 10% • 25%
No significant change • 25%
Decrease by less than 5% • 25%
Decrease by 5-10% • 25%